Discounted Cash Flow Rating

Buy

Return on Equity Rating

Strong Sell

Debt to Equity Rating

Buy

Price to Earnings Rating

Strong Sell

Analyst Rating

Neutral

Simple Moving Average

Neutral

Exponential Moving Average

Neutral

Relative Strength Index

Standard Deviation

Strong Sell

Williams %R

Strong Buy

Average Directional Index

Strong Sell

Insider Trading

Neutral

Wall Street Data Solutions Rating

Sell

C

RPT Realty Common Shares of Beneficial Interest (MD) (RPT)

Real Estate Investment Trusts

https://www.rptrealty.com

RPT Realty is a self-managed real estate investment trust that invests in and manages retail properties. The company owns and operates a national portfolio of open-air shopping destinations principally located in top U.S. markets. The Company's shopping centers offer diverse, locally-curated consumer experiences that reflect the lifestyles of their surrounding communities and meet the modern expectations of the Company's retail partners. The Company's property portfolio consisted of 44 wholly-owned shopping centers, 13 shopping centers owned through its grocery-anchored joint venture, 48 retail properties owned through its net lease joint venture and one net lease retail property that was held for sale by the Company which together represent 15.0 million square feet of gross leasable area.

19 W 44TH STREET, SUITE 1002
NEW YORK, NY

Current Price

---.--

% Change Today

0.00%

Change Amt. Today

0.00

Active Status

Active

Listing Date

12/28/1988

Market Cap

1,112,416,220

Shares Outstanding

85,710,000

Weighted SO

86,704,298

Total Employees

N/A

Upcoming Earnings

N/A

Beta

1.6440

Last Div

0.5600

Range

8.62-13.79

Chg

-0.3300

Avg Vol

1423596

Mkt Cap

1112416220

Exch

NYSE

Country

US

Phone

212-221-1261

DCF Diff

0.7071

DCF

11.0971

Div Yield

0.0152

P/S

5.3039

EV Multiple

19.2553

P/FV

1.1915

Div Yield %

1.5155

P/E

20.5081

PEG

0.9741

Payout

1.0111

Current Ratio

0.3283

Quick Ratio

0.6709

Cash Ratio

0.0594

DSO

31.9813

DIO

-134.1216

Op Cycle

-102.1403

DPO

297.8071

CCC

-399.9474

Gross Margin

0.6839

Op Margin

0.1502

Pretax Margin

0.2616

Net Margin

0.2556

Eff Tax Rate

0.0042

ROA

0.0281

ROE

0.0570

ROCE

0.0171

NI/EBT

0.9773

EBT/EBIT

1.7417

EBIT/Rev

0.1502

Debt Ratio

0.4678

D/E

0.9679

LT Debt/Cap

0.4839

Total Debt/Cap

0.4918

Int Coverage

0.8929

CF/Debt

0.0988

Equity Multi

2.0688

Rec Turnover

11.4129

Pay Turnover

1.2256

Inv Turnover

-2.7214

FA Turnover

12.5148

Asset Turnover

0.1099

OCF/Share

1.0297

FCF/Share

0.5863

Cash/Share

0.3327

OCF/Sales

0.4208

FCF/OCF

0.5693

CF Coverage

0.0988

ST Coverage

3.1519

CapEx Coverage

2.3220

Div&CapEx Cov

0.9570

P/BV

1.1915

P/B

1.1915

P/S

5.3039

P/E

20.5081

P/FCF

22.1394

P/OCF

12.4594

P/CF

12.4594

PEG

0.9741

P/S

5.3039

EV Multiple

19.2553

P/FV

1.1915

DPS

0.1944

Latest Headlines (EST)

GlobeNewswire Inc. Jun 26, 21:45 DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Sarepta Therapeutics GlobeNewswire Inc. Jun 26, 21:38 Sarepta Therapeutics, Inc. Investors: Please contact the Portnoy Law Firm to recover your losses. August 25, 2025 Deadline to file Lead Plaintiff Motion. Benzinga Jun 26, 21:25 SRPT Investors Have Opportunity to Lead Sarepta Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm The Motley Fool Mar 25, 21:31 Why Investors Thought Freshpet Stock Was a bad boy Today GlobeNewswire Inc. Mar 18, 22:16 Sarepta Therapeutics, Inc. Investors: Company Investigated by the Portnoy Law Firm The Motley Fool Mar 14, 01:23 Why Freshpet Was a Dog of a Stock This Week The Motley Fool Jan 22, 17:47 Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today The Motley Fool Jan 22, 17:47 Why Sarepta Therapeutics Stock Zoomed Nearly 5% Higher Today Zacks Investment Research Jan 22, 14:42 AstraZeneca's (AZN) Imfinzi Combo Meets Liver Cancer Study Goal Zacks Investment Research Jan 19, 13:09 TransCode (RNAZ) Down 50% on Issue of New Common Stock Zacks Investment Research Jan 15, 12:27 Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why Zacks Investment Research Jan 15, 12:27 Iovance (IOVA) Surges More Than 150% in 3 Months: Here's Why Benzinga Jan 09, 12:58 Sarepta Expects Prelim Gene Therapy Revenue To Be $131M In Q4, $200M For Fiscal Year The Motley Fool Jan 05, 17:14 Why Freshpet Stock Was Up 22% in December Benzinga Jan 04, 14:08 Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024 Zacks Investment Research Jan 01, 12:00 What Makes Freshpet (FRPT) a New Buy Stock Zacks Investment Research Dec 29, 08:44 Sarepta (SRPT): Strong Industry, Solid Earnings Estimate Revisions The Motley Fool Dec 28, 10:07 3 Things About Sarepta Therapeutics Every Smart Investor Knows The Motley Fool Dec 28, 10:07 3 Things About Sarepta Therapeutics Every Smart Investor Knows Zacks Investment Research Dec 26, 11:35 Sarepta (SRPT) Seeks Label Expansion for DMD Gene Therapy

Revenue Product Segmentation